Forbes List of Neurological Drugs to Watch: Corante

About this author

Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev

Receive by email

GUEST AUTHOR ARCHIVES

RECENT ENTRIES

› Chinese Cover of The Neuro Revolution

› The Neuro Revolution Lands In China

› How Neuroscience Will Change the World - My Interview on Reason.tv

› Neuroscience Hearing on Capitol Hill Wednesday Sept 29, 2pm

› The Neuro Revolution Published in Japan as "Neuro Wars"

› Neurotech 2010: Translational Researchers Highlight Innovation

› The Neuro Revolution in China Progressing

› Speakers for Neurotech 2010 - Boston, May 19-20

› Giving the Brain a Voice: NIO Public Policy Tour in DC tomorrow

› McGovern Institue for Brain Research at MIT Goes Web 2.0

› RECENT COMMENTS [xml]

› Ivon Alexander Nestoly on
Emerging Neurosociety Driven by Neuronanotechnology

› joe on
Center for Neurotechnology Studies Launched at Potomac Institute for Policy Studies

› becca on
Neural Prosthetics Algorithm Advance

› Sam on
The End of Abuse - Recognizing Addiction as a Disease Act of 2007

› Tony on
A Scary Illusion - Mr. Angry and Ms. Calm

› Andy Lautin on
NERV - NASDAQ NeuroInsights Neurotech Index is Live

› CATEGORIES

› Blink › (55) [xml]
› Brain Foundations (13) [xml]
› Casey's Insights (5) [xml]
› Cogniceuticals (29) [xml]
› Culture & the Brain (10) [xml]
› Economic Geography (6) [xml]
› Emoticeuticals (18) [xml]
› Interviews/Press (11) [xml]
› Mental Health Issues (71) [xml]
› NBIC 03-04-05 (20) [xml]
› NERV - Neurotech Index (2) [xml]
› Neuro Revolution (18) [xml]
› Neurodevices (36) [xml]
› Neurodiagnostics (34) [xml]
› Neuroeconomics (16) [xml]
› Neuroesthetics (24) [xml]
› Neuroethics (57) [xml]
› Neurofinance (15) [xml]
› NeuroInsights (9) [xml]
› Neurolaw (2) [xml]
› Neuromarketing (12) [xml]
› Neuropharma (49) [xml]
› Neuropolicy (20) [xml]
› Neurosociety (86) [xml]
› Neurotech Industry (61) [xml]
› Neurotheology (2) [xml]
› Neurowarfare (2) [xml]
› NeuroWave 2050 (23) [xml]
› NIO (35) [xml]
› Perception Shift (17) [xml]
› Press (1) [xml]
› Protein/Gene Chips (11) [xml]
› Public Neurotech News (5) [xml]
› Sensoceutical Market (1) [xml]
› SF Focus (6) [xml]
› TV (1) [xml]
› VC for Neurotech (3) [xml]
› Writing & Blogging (23) [xml]
› X-tra (39) [xml]

› ARCHIVES

› August 2011 (2)
› October 2010 (1)
› September 2010 (2)
› July 2010 (1)
› June 2010 (1)
› April 2010 (1)
› March 2010 (2)
› February 2010 (2)
› January 2010 (1)
› December 2009 (3)
› November 2009 (1)
› October 2009 (4)
› September 2009 (4)
› August 2009 (6)
› July 2009 (7)
› June 2009 (7)
› May 2009 (5)
› April 2009 (3)
› March 2009 (4)
› February 2009 (5)
› January 2009 (6)
› December 2008 (3)
› November 2008 (5)
› October 2008 (3)
› September 2008 (3)
› August 2008 (5)
› July 2008 (4)
› June 2008 (9)
› May 2008 (11)
› April 2008 (5)
› March 2008 (1)
› February 2008 (6)
› January 2008 (3)
› December 2007 (4)
› November 2007 (5)
› October 2007 (8)
› September 2007 (6)
› August 2007 (8)
› July 2007 (6)
› June 2007 (4)
› May 2007 (4)
› April 2007 (5)
› March 2007 (5)
› February 2007 (8)
› January 2007 (6)
› December 2006 (6)
› November 2006 (8)
› October 2006 (3)
› September 2006 (9)
› August 2006 (8)
› July 2006 (13)
› June 2006 (11)
› May 2006 (8)
› April 2006 (11)
› March 2006 (10)
› February 2006 (7)
› January 2006 (10)
› December 2005 (6)
› November 2005 (21)
› October 2005 (15)
› September 2005 (15)
› August 2005 (12)
› July 2005 (15)
› June 2005 (15)
› May 2005 (16)
› April 2005 (3)
› March 2005 (15)
› February 2005 (19)
› January 2005 (19)
› December 2004 (8)
› November 2004 (9)
› October 2004 (8)
› September 2004 (11)
› August 2004 (11)
› July 2004 (20)
› June 2004 (14)
› May 2004 (17)
› April 2004 (21)
› March 2004 (33)
› February 2004 (17)
› January 2004 (13)
› December 2003 (17)
› November 2003 (19)
› October 2003 (21)
› September 2003 (22)
› August 2003 (15)
› July 2003 (26)
› June 2003 (20)
› May 2003 (21)
› April 2003 (24)
› March 2003 (25)
› February 2003 (5)

In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

January 29, 2004

Forbes List of Neurological Drugs to Watch

Posted by Zack

Forbes has a nice overview of seven neurological drugs that are in mid to late stage clinical trials:

Multiple sclerosis Late-stage - Antegren - Biogen Idec, Elan
Alzheimer's disease Mid-stage - Clioquinol - Prana Biotech
Alzheimer's disease Mid-stage - CX516 - Cortex Pharma
Depression, urinary incontinence Late-stage - Duloxetine - Lilly
Epilepsy, neuropathic pain, anxiety Late-stage - Pregabalin - Pfizer
Smoking addiction Late-stage - Varenicline - Pfizer

Category: Mental Health Issues

COMMENTS

propecia on October 12, 2004 03:06 PM writes...

99 little bugs in the code, 99 bugs in the code,
fix one bug, compile it again...
101 little bugs in the code....
buy propecia cheap propeciaHand, n.:
A singular instrument worn at the end of a human arm and
commonly thrust into somebody's pocket.
-- Ambrose Bierce, "The Devil's Dictionary"
propecia propecia online Propecia $0.99 Per Pill 99 little bugs in the code, 99 bugs in the code,
fix one bug, compile it again...
101 little bugs in the code....

Permalink to Comment

TRACKBACKS

TrackBack URL: http://www.corante.com/cgi-bin/mt/mt-tb.cgi/1055

RELATED ENTRIES

About this author

Receive by email

GUEST AUTHOR ARCHIVES

THE NEURO REVOLUTION

NEUROTECH REPORT

NEUROTECH NEWS

BLOGS I READ

NEURORESOURCE LINKS

NEWS SOURCES

ORGANIZATIONS

Zack on Twitter